Scientific validation of FEP projects in Flare™
It is often the case in drug discovery that a new hit series of compounds against a therapeutic target must ...
Cresset is delighted to announce the appointment of Dr Robert Scoffin as Chief Executive Officer of Cresset Group. Rob joins Cresset from CambridgeSoft where, as Vice President of European Operations, he was responsible for significant growth in CambridgeSoft’s European business. Rob replaces Beatrice Leigh, who will now become non-executive Chairman of the Board.
“The appointment of Rob marks an exciting new chapter for Cresset,” said Andy Vinter, Founder and Chief Scientific Officer of Cresset. “Rob has a long track record of close collaboration with customers and successful commercial growth in the computational chemistry market place.” Outgoing CEO and Chairman of the Board, Bea Leigh commented, “We are excited to be working with Rob to further accelerate the company’s development and to achieve our aggressive corporate objectives”.
“This is a fantastic opportunity to join an established company with an excellent scientific reputation, and to help drive growth and enhanced commercial success in the future,” said Rob. “The Cresset team has worked hard to create a world-leading portfolio of products, and I am looking forward to helping bring those to new markets.”
Rob has a DPhil in chemistry from Oxford and has recently been instrumental in the development of Electronic Lab Notebook systems which he has deployed at several major pharmaceutical companies. Prior to CambridgeSoft, Rob was CEO (Software) for Amedis and Senior Product Manager at Oxford Molecular.